NDA 204630 · Provepharm Sas
Provayblue
Methylene Blue · Intravenous
Accelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: Dec 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 8, 2016
Approved uses
2
Original approval plus efficacy supplements
Registered trials
131
26 Phase 3, 11 recruiting
FAERS reports
1,578
1,470 serious, 257 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids. [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 )]. WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS See full prescribing information for complete boxed warning. PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase...
What it is approved for
From the label in effect May 28, 2025.
PROVAYBLUE is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. PROVAYBLUE (methylene blue) is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
Mechanism: Methylene blue is a water soluble thiazine dye that promotes a non-enyzmatic redox conversion of metHb to hemoglobin. In situ, methylene blue is first converted to leucomethylene blue (LMB) via NADPH reductase. It is the LMB molecule which then reduces the ferric iron of metHb to the ferrous state of normal hemoglobin.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 8, 2024 Supplement 21 · Efficacy OrphanLabel
- Apr 8, 2016 Original approval · Type 5 - New Formulation or New Manufacturer Accelerated approvalOrphanReviewSummary ReviewLetter
2 products under this application
- PROVAYBLUE · METHYLENE BLUE 50MG/10ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- PROVAYBLUE · METHYLENE BLUE 10MG/2ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Methylene Blue" as an intervention, any sponsor and status, largest first.
- The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance ColonoscopyPivotal-lookingCompleted
Cosmo Technologies LtdIndustry
NCT01694966 · 1,249 participants · Start Sep 2013 · Primary completion Oct 2016
Drug: Methylene Blue MMX®; Placebo · For: Colorectal Cancer
Sites: Phoenix, Arizona; Scottsdale, Arizona; Lafayette, Colorado · 19 sites in all
- Clinical Evaluation of Patient Preoperative PrepPivotal-lookingCompleted
Zurex Pharma, Inc.Industry
NCT02831816 · 640 participants · Start Aug 3, 2016 · Primary completion Aug 3, 2017
Drug: ZuraPrep; ChloraPrep and 1 more · For: Surgical Skin Preparation
Sites: Bozeman, Montana
- Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic ShockPivotal-lookingRecruiting
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT06481410 · 488 participants (planned) · Start Jun 22, 2024 · Primary completion Dec 31, 2027
Drug: Methylene Blue Intervention Group; Normal Saline Control Group · For: Septic Shock; Methylene Blue; Sepsis
Sites: Hangzhou, China
- Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve GastrectomyPivotal-lookingRecruiting
Tanta UniversityAcademic, hospital or other
NCT06810882 · 482 participants (planned) · Start Feb 16, 2025 · Primary completion Feb 16, 2027
Drug: Perineural ondansetron; Intravenous ondansetron · For: Ondansetron; Laparoscopic; Gastrectomy
Sites: Tanta, Egypt
- In-vivo Efficacy of Patient Preoperative PrepPivotal-lookingCompleted
Zurex Pharma, Inc.Industry
NCT02831998 · 440 participants · Start Jul 27, 2016 · Primary completion Apr 9, 2017
Drug: ZuraPrep; ChloraPrep and 1 more · For: Surgical Skin Preparation
Sites: Sterling, Virginia
- Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 PatientsPivotal-lookingCompleted
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaAcademic, hospital or other
NCT04621123 · 384 participants · Start Nov 10, 2020 · Primary completion May 31, 2021
Drug: Convalescent anti-SARS-CoV-2 MBT plasma · For: SARS-CoV-2 Infection; Safety and Efficacy
Sites: Badalona, Spain; Berga, Spain; Manresa, Spain · 4 sites in all
- Methylene Blue in Severe Sepsis and Septic ShockPivotal-lookingStatus unknown
Seoul National University HospitalAcademic, hospital or other
NCT01797978 · 354 participants (planned) · Start Feb 2013 · Primary completion Jan 2016
Drug: Intravenous methylene blue administration; Placebo · For: Severe Sepsis; Septic Shock
Sites: Seongnam-si, South Korea; Seoul, South Korea · 3 sites in all
- Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of DysuriaPivotal-lookingCompleted
EMSIndustry
NCT01657448 · 316 participants · Start Jun 27, 2016 · Primary completion Nov 21, 2016
Drug: Methenamine and Methylthioninium chloride; Phenazopyridine · For: Dysuria
Sites: Porto Alegre, Brazil; São José dos Campos, Brazil; São Paulo, Brazil · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- serotonin syndrome469
- drug interaction358
- drug ineffective309
- hypotension208
- off label use185
- toxicity to various agents141
- overdose107
- intentional overdose100
- encephalopathy82
- acute kidney injury76
- toxic encephalopathy76
- blood creatine phosphokinase increased72
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 4 |
| 2006 | 7 |
| 2007 | 11 |
| 2008 | 13 |
| 2009 | 25 |
| 2010 | 38 |
| 2011 | 24 |
| 2012 | 23 |
| 2013 | 33 |
| 2014 | 19 |
| 2015 | 41 |
| 2016 | 72 |
| 2017 | 68 |
| 2018 | 77 |
| 2019 | 78 |
| 2020 | 101 |
| 2021 | 96 |
| 2022 | 146 |
| 2023 | 180 |
| 2024 | 162 |
| 2025 | 248 |
| 2026 | 103 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial.
Ibarra-Estrada M, Kattan E, Aguilera-González P, et al. · Crit Care 2023 · Randomized Controlled Trial
- Methylene Blue in Septic Shock: A Systematic Review and Meta-Analysis.
Fernando SM, Tran A, Soliman K, et al. · Crit Care Explor 2024 · Systematic Review, Meta-Analysis
- Methylene blue in sepsis and septic shock: a systematic review and meta-analysis.
Ballarin RS, Lazzarin T, Zornoff L, et al. · Front Med (Lausanne) 2024 · Systematic Review
- Methylene Blue Reduces Mortality in Critically Ill and Perioperative Patients: A Meta-Analysis of Randomized Trials.
Pruna A, Bonaccorso A, Belletti A, et al. · J Cardiothorac Vasc Anesth 2024 · Meta-Analysis, Review
- Methylene Blue for Septic Shock: A Systematic Review and Meta-analysis of Randomized and Prospective Observational Studies.
Alkazemi A, Almoosawy SA, Murad A, et al. · J Intensive Care Med 2026 · Meta-Analysis, Systematic Review
- The use of methylene blue in adult patients with septic shock: a systematic review and meta-analysis.
Ng KT, Kwok PE, Lim WE, et al. · Braz J Anesthesiol 2025 · Systematic Review, Meta-Analysis
Sponsor: Provepharm Sas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.